Back to Search
HYAM LEVITSKY, M.D.
M.D.
Medical Oncology Physician
NPI: 1437199221Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D34963(MD)
Research & Publications (20)
Augmentation of host immune responses to cancer: overcoming the barrier of tumor antigen-specific T-cell tolerance.
PMID 10874499·Cancer J·2000
6-review
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).
PMID 19556425·Blood·2009
3-trial
Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand.
PMID 19535642·J Immunol·2009
7-preclinical
Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes.
PMID 19276358·Cancer Res·2009
7-preclinical
Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation.
PMID 18063750·Blood·2008
7-preclinical
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer.
PMID 18794521·Proc Natl Acad Sci U S A·2008
7-preclinical
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells.
PMID 18410892·Biol Blood Marrow Transplant·2008
7-preclinical
Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.
PMID 18286505·Cancer·2008
8-other
Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).
PMID 17916465·Vaccine·2007
6-review
Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance.
PMID 17277120·J Immunol·2007
7-preclinical
Vaccinia virus preferentially infects and controls human and murine ovarian tumors in mice.
PMID 16915291·Gene Ther·2007
7-preclinical
Magnetoelectroporation: improved labeling of neural stem cells and leukocytes for cellular magnetic resonance imaging using a single FDA-approved agent.
PMID 17292120·Nanomedicine·2006
7-preclinical
In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
PMID 16339406·Blood·2006
7-preclinical
Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
PMID 16179369·Blood·2006
4-observational
Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors.
PMID 15753403·Cancer Res·2005
8-other
Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.
PMID 15596524·J Exp Med·2004
7-preclinical
Synopsis of the 6th Walker's Cay Colloquium on Cancer Vaccines and Immunotherapy.
PMID 15212694·J Transl Med·2004
8-other
Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells.
PMID 12778137·Nat Med·2003
7-preclinical
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras.
PMID 12406877·Blood·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1437199221
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile